



## **Acarix Chairman Jan Poulsen Acquires Shares**

**I the period 15. – 18. September, Jan Poulsen privately purchased 475,000 shares at an average price of SEK 0.3053.**

**Following this transaction, Jan Poulsen privately owns 1,647,815 shares and through 100% owned companies an additional 40,964,661 shares bringing his total holdings to 42,612,476 shares. His spouse has in the same period purchased 280,000 shares, and she now owns 427,006 shares.**

### **About Acarix**

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 40,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit [www.acarix.com](http://www.acarix.com)

### **For more information, contact**

Macie May, phone +1 405 517 5161, email [mmay@saxum.com](mailto:mmay@saxum.com)

### **Attachments**

[Acarix Chairman Jan Poulsen Acquires Shares](#)